Acne inversa/Hidradenitis suppurativa – Von der Pathogenese zur Therapie

Zusammenfassung

Acne inversa/Hidradenitis suppurativa (AI/HS) ist eine chronisch-entzündliche Hauterkrankung, die durch das rezidivierende Auftreten von entzündlichen Knoten, Abszessen, Fistelgängen und Narben v. a. in der Axillär-, Inguinal- und Perianalregion charakterisiert ist. In den letzten Jahren rückte die Erforschung der pathophysiologischen Grundlagen der AI/HS zunehmend in den wissenschaftlichen Fokus. Parallel dazu wurde die Wirksamkeit neuer anti-inflammatorischer Therapien in klinischen Studien untersucht, die zum Teil schon Eingang in die klinische Routine gefunden haben. Schwerpunkt dieses Review ist es, den aktuellen Stand der AI/HS zugrundliegenden pathophysiologischen Mechanismen darzustellen und die sich daraus ergebenden Konsequenzen sowohl für die konservative als auch für die operative Therapie abzuleiten.

Abstract

Acne inversa/hidradenitis suppurativa is a chronic inflammatory skin disease characterized by the appearance of subcutaneous inflammatory nodules, abscesses and formation of fistulas, sinus tracts and contracting scars. In the last years scientific interest in its pathophysiology has increasingly gained interest and numerous reports have aimed to identify crucial aspects leading to the ongoing inflammation. In parallel, new systemic therapeutic approaches have been reported targeting the inflammatory component of the disease. The aim of this review is to give an overview of the clinical presentation and the current knowledge on pathophysiology with a focus on the immune system fueling chronic cutaneous inflammation. Moreover, systemic anti-inflammatory therapy and surgical interventions are described and presented in the context of pathophysiological changes.

^* A. Schuch und M. Absmaier-Kijak: Geteilte Erstautorenschaft, beide Autorinnen haben in gleichem Maße zur Publikation beigetragen

• Literatur

• 1 Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60: 539-561 quiz 562-533
• 2 Saunte DML, Jemec GBE. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA 2017; 318: 2019-2032
• 3 Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366: 158-164
• 4 Mühlstädt M, Bechara FG, Kunte C. Acne inversa (Hidradenitis suppurativa) Erkennen – Verstehen – Therapieren. Hautarzt 2013; 64: 55-61 ; quiz 62
• 5 Kirschke J, Hessam S, Bechara FG. Hidradenitis suppurativa/Acne inversa: Ein Update. Hautarzt 2015; 66: 413-422
• 6 Zouboulis CC, Del Marmol V, Mrowietz U. et al. Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation. Dermatology 2015; 231: 184-190
• 7 Kromann CB, Ibler KS, Kristiansen VB. et al. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol 2014; 94: 553-557
• 8 Garg A, Papagermanos V, Midura M. et al. Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A. Br J Dermatol 2018; 178: 709-714
• 9 Seyed Jafari SM, Knusel E, Cazzaniga S. et al. A Retrospective Cohort Study on Patients with Hidradenitis Suppurativa. Dermatology 2018; 234: 71-78
• 10 Fitzsimmons JS, Guilbert PR. A family study of hidradenitis suppurativa. J Med Genet 1985; 22: 367-373
• 11 Pink AE, Simpson MA, Desai N. et al. Mutations in the gamma-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol 2012; 132: 2459-2461
• 12 Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH. , Hrsg. Dermatologic Surgery. New York: Marcel Dekker; 1989: 729-739
• 13 Sartorius K, Emtestam L, Jemec GB. et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161: 831-839
• 14 Kimball AB, Jemec GB, Yang M. et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol 2014; 171: 1434-1442
• 15 Zouboulis CC, Tzellos T, Kyrgidis A. et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017; 177: 1401-1409
• 16 Hessam S, Scholl L, Sand M. et al. A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa. JAMA Dermatol 2018; 154: 330-335
• 17 Jemec GB, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. J Am Acad Dermatol 2015; 73: S4-7
• 18 Revuz JE, Canoui-Poitrine F, Wolkenstein P. et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601
• 19 Delany E, Gormley G, Hughes R. et al. A cross-sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP). J Eur Acad Dermatol Venereol 2018; 32: 467-473
• 20 Garg A, Kirby JS, Lavian J. et al. Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States. JAMA Dermatol 2017; 153: 760-764
• 21 Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-194
• 22 Canoui-Poitrine F, Revuz JE, Wolkenstein P. et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61: 51-57
• 23 Saunte DM, Boer J, Stratigos A. et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 2015; 173: 1546-1549
• 24 Vazquez BG, Alikhan A, Weaver AL. et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013; 133: 97-103
• 25 Wolkenstein P, Loundou A, Barrau K. et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-623
• 26 Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010; 90: 264-268
• 27 Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011; 91: 328-332
• 28 Matusiak L. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol 2018;
• 29 Kurek A, Peters EM, Chanwangpong A. et al. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol 2012; 67: 422-428 428.e421.
• 30 Konety BR, Cooper T, Flood HD. et al. Scrotal elephantiasis associated with hidradenitis suppurativa. Plast Reconstr Surg 1996; 97: 1243-1245
• 31 Micieli R, Alavi A. Lymphedema in patients with hidradenitis suppurativa: a systematic review of published literature. Int J Dermatol 2018; 57: 1471-1480
• 32 Hessam S, Sand M, Bechara FG. When inflammation shifts to malignancy: extensive squamous cell carcinoma in a female hidradenitis suppurativa/acne inversa patient. J Dtsch Dermatol Ges 2017; 15: 86-88
• 33 Lavogiez C, Delaporte E, Darras-Vercambre S. et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology 2010; 220: 147-153
• 34 Kurzen H, Kurokawa I, Jemec GBE. et al. What causes hidradenitis suppurativa?. Experimental Dermatology 2008; 17: 455-472
• 35 Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: An update. J Am Acad Dermatol 2015; 73: S8-11
• 36 Vossen A, van der Zee HH, Prens EP. Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. Front Immunol 2018; 9: 2965
• 37 von Laffert M, Helmbold P, Wohlrab J. et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010; 19: 533-537
• 38 von Laffert M, Stadie V, Wohlrab J. et al. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011; 164: 367-371
• 39 Hotz C, Boniotto M, Guguin A. et al. Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa. J Invest Dermatol 2016; 136: 1768-1780
• 40 Kamp S, Fiehn AM, Stenderup K. et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol 2011; 164: 1017-1022
• 41 van der Zee HH, de Ruiter L, Boer J. et al. Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br J Dermatol 2012; 166: 98-106
• 42 Lima AL, Karl I, Giner T. et al. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br J Dermatol 2016; 174: 514-521
• 43 Wolk K, Warszawska K, Hoeflich C. et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 2011; 186: 1228-1239
• 44 van der Zee HH, de Ruiter L, van den Broecke DG. et al. Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br J Dermatol 2011; 164: 1292-1298
• 45 Schlapbach C, Hanni T, Yawalkar N. et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65: 790-798
• 46 Thomi R, Yerly D, Yawalkar N. et al. Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa. Br J Dermatol 2017; 177: 1358-1366
• 47 Thomi R, Kakeda M, Yawalkar N. et al. Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2017; 31: 2091-2096
• 48 Hessam S, Sand M, Gambichler T. et al. Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop. Br J Dermatol 2018; 178: 761-767
• 49 Dostert C, Grusdat M, Letellier E. et al. The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond. Physiol Rev 2019; 99: 115-160
• 50 Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?. Acta Derm Venereol 2009; 89: 601-603
• 51 Riis PT, Soeby K, Saunte DM. et al. Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients. Arch Dermatol Res 2015; 307: 885-889
• 52 Wolk K, Wenzel J, Tsaousi A. et al. Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. Br J Dermatol 2017; 177: 1385-1393
• 53 Matusiak L, Szczech J, Bieniek A. et al. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J Am Acad Dermatol 2017; 76: 670-675
• 54 Moran B, Sweeney CM, Hughes R. et al. Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy. J Invest Dermatol 2017; 137: 2389-2395
• 55 Chung Y, Chang SH, Martinez GJ. et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009; 30: 576-587
• 56 Ikeda S, Saijo S, Murayama MA. et al. Excess IL-1 signaling enhances the development of Th17 cells by downregulating TGF-beta-induced Foxp3 expression. J Immunol 2014; 192: 1449-1458
• 57 Hana A, Booken D, Henrich C. et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 2007; 80: 2214-2220
• 58 Esser C, Rannug A, Stockinger B. The aryl hydrocarbon receptor in immunity. Trends Immunol 2009; 30: 447-454
• 59 van der Zee HH, Laman JD, Boer J. et al. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 2012; 21: 735-739
• 60 Nikota JK, Shen P, Morissette MC. et al. Cigarette smoke primes the pulmonary environment to IL-1alpha/CXCR-2-dependent nontypeable Haemophilus influenzae-exacerbated neutrophilia in mice. J Immunol 2014; 193: 3134-3145
• 61 Sabat R, Chanwangpong A, Schneider-Burrus S. et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 2012; 7: e31810
• 62 Yang H, Youm YH, Vandanmagsar B. et al. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J Immunol 2010; 185: 1836-1845
• 63 Chehimi M, Vidal H, Eljaafari A. Pathogenic Role of IL-17-Producing Immune Cells in Obesity, and Related Inflammatory Diseases. J Clin Med 2017; 6
• 64 Wong VW, Akaishi S, Longaker MT. et al. Pushing back: wound mechanotransduction in repair and regeneration. J Invest Dermatol 2011; 131: 2186-2196
• 65 Mader JS, Ewen C, Hancock RE. et al. The human cathelicidin, LL-37, induces granzyme-mediated apoptosis in regulatory T cells. J Immunother 2011; 34: 229-235
• 66 Emelianov VU, Bechara FG, Glaser R. et al. Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol 2012; 166: 1023-1034
• 67 Thomi R, Schlapbach C, Yawalkar N. et al. Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1/Th17 immune response. Exp Dermatol 2018; 27: 172-177
• 68 Ring HC, Thorsen J, Saunte DM. et al. The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls. JAMA Dermatol 2017; 153: 897-905
• 69 Zouboulis CC, Desai N, Emtestam L. et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29: 619-644
• 70 Clemmensen OJ. Topical Treatment of Hidradenitis Suppurativa with Clindamycin. Int J Dermatol 1983; 22: 325-328
• 71 Zouboulis CC, Bechara FG, Dickinson-Blok JL. et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol 2019; 33: 19-31
• 72 Zouboulis CC, Bechara FG, Fritz K. et al. [S1 guideline for the treatment of hidradenitis suppurativa/acne inversa* (number ICD-10 L73.2)]. J Dtsch Dermatol Ges 2012; 10 (Suppl. 05) S1-S31
• 73 Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998; 39: 971-974
• 74 Dessinioti C, Zisimou C, Tzanetakou V. et al. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. Clin Exp Dermatol 2016; 41: 852-857
• 75 Bettoli V, Zauli S, Borghi A. et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol 2014; 28: 125-126
• 76 Gener G, Canoui-Poitrine F, Revuz JE. et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009; 219: 148-154
• 77 van der Zee HH, Boer J, Prens EP. et al. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009; 219: 143-147
• 78 Pasquale TR, Tan JS. Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 2005; 40: 127-135
• 79 Ziglam HM, Daniels I, Finch RG. Immunomodulating activity of rifampicin. J Chemother (Florence, Italy) 2004; 16: 357-361
• 80 Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic medications. J Am Acad Dermatol 2015; 73: S82-88
• 81 Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012; 119: 651-665
• 82 Kimball AB, Kerdel F, Adams D. et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012; 157: 846-855
• 83 Kimball AB, Okun MM, Williams DA. et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 2016; 375: 422-434
• 84 Zouboulis CC, Okun MM, Prens EP. et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol 2019; 80: 60-69 e62
• 85 Grant A, Gonzalez T, Montgomery MO. et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-217
• 86 Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2012; 26: 911-914
• 87 Blok JL, Li K, Brodmerkel C. et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol 2016; 174: 839-846
• 88 Kovacs M, Podda M. Guselkumab in the treatment of severe Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2019; 33: e140-e141
• 89 Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol 2018; 179: 182-185
• 90 Schuch A, Fischer T, Boehner A. et al. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab. Acta Derm Venereol 2018; 98: 151-152
• 91 Jorgensen AR, Yao Y, Thomsen SF. Therapeutic Response to Secukinumab in a 36-Year-Old Woman with Hidradenitis Suppurativa. Case Rep Dermatol Med 2018; 2018: 8685136
• 92 Giuseppe P, Nicola P, Valentina C. et al. A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with Secukinumab. Ann Dermatol 2018; 30: 462-464
• 93 Odorici G, Pellacani G, Conti A. Ixekizumab in hidradenitis suppurativa: a case report in a psoriatic patient. G Ital Dermatol Venereol 2019;
• 94 Kirsten N, Augustin M. Hidradenitis suppurativa successfully treated with ixekizumab – presentation of 2 cases. Exp Dermatol 2019; 28: 23-23
• 95 Leslie KS, Tripathi SV, Nguyen TV. et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol 2014; 70: 243-251
• 96 Tzanetakou V, Kanni T, Giatrakou S. et al. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial. JAMA Dermatol 2016; 152: 52-59
• 97 Theut Riis P, Thorlacius LR, Jemec GB. Investigational drugs in clinical trials for Hidradenitis Suppurativa. Exp Opin Invest Drug 2018; 27: 43-53
• 98 Bechara FG, Hessam S. [Hidradenitis suppurativa]. MMW Fortschr Med 2016; 158: 52-53
• 99 Scholl L, Hessam S, Reitenbach S. et al. Operative Behandlungsoptionen bei Hidradenitis suppurativa/Acne inversa. Hautarzt 2018; 69: 149-161
• 100 Ritz JP, Runkel N, Haier J. et al. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis 1998; 13: 164-168
• 101 van Straalen KR, Schneider-Burrus S, Prens EP. Current and future treatment of hidradenitis suppurativa. Br J Dermatol 2018;
• 102 Scholl L, Hessam S, Bergmann U. et al. Surgical Treatment of Sinus Tracts and Fistulas in Perianal Hidradenitis Suppurativa. J Cutan Med Surg 2018; 22: 239-241
• 103 Parks RW, Parks TG. Pathogenesis, clinical features and management of hidradenitis suppurativa. Ann R Coll Surg Engl 1997; 79: 83-89
• 104 Weyandt G. Operative Therapie der Acne inversa. Hautarzt 2005; 56: 1033-1039
• 105 Buyukasik O, Hasdemir AO, Kahramansoy N. et al. Surgical approach to extensive hidradenitis suppurativa. Dermatol Surg 2011; 37: 835-842
• 106 Alharbi Z, Kauczok J, Pallua N. A review of wide surgical excision of hidradenitis suppurativa. BMC Dermatol 2012; 12: 9
• 107 Posch C, Monshi B, Quint T. et al. The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients. J Am Acad Dermatol 2017; 77: 123-129 e125
• 108 Humphries LS, Kueberuwa E, Beederman M. et al. Wide excision and healing by secondary intent for the surgical treatment of hidradenitis suppurativa: A single-center experience. J Plast Reconstr Aesthet Surg 2016; 69: 554-566
• 109 Kofler L, Schweinzer K, Heister M. et al. Surgical treatment of hidradenitis suppurativa: an analysis of postoperative outcome, cosmetic results and quality of life in 255 patients. J Eur Acad Dermatol Venereol 2018; 32: 1570-1574
• 110 van Rappard DC, Mooij JE, Mekkes JR. Mild to moderate hidradenitis suppurativa treated with local excision and primary closure. J Eur Acad Dermatol Venereol 2012; 26: 898-902
• 111 Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 2000; 26: 638-643
• 112 Ulrich A, Hildebrandt U, Ulrich J. Acne inversa: Einfluss assoziierter Faktoren auf den Schweregrad und das operative Ergebnis. Hautarzt 2014; 65: 623-627
• 113 Mehdizadeh A, Hazen PG, Bechara FG. et al. Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis. J Am Acad Dermatol 2015; 73: S70-S77
• 114 Kelly G, Hughes R, McGarry T. et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol 2015; 173: 1431-1439
• 115 DeFazio MV, Economides JM, King KS. et al. Outcomes After Combined Radical Resection and Targeted Biologic Therapy for the Management of Recalcitrant Hidradenitis Suppurativa. Ann Plast Surg 2016; 7: 217-222